GlaxoSmithKline Intellectual Property Development Limited
发明人:
申请号：
EP19214674.4
公开号：
EP3650019A1
申请日:
2015.05.27
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
The present invention relates to pharmaceutical products comprising fluticasone furoate for use in the treatment of COPD patients, particularly a subgroup of COPD patients that through analysis have been identified as possessing an eosinophil blood count of ≥150 cells/µl. The present invention is further directed to methods for treating a patient with COPD which methods include identifying a patient that will respond to treatment and administering a pharmaceutical product of the present invention comprising fluticasone furoate to said patient.
